ArticleFrontiers in oncology2026
Lymphoma-associated pancreatitis: a multicenter retrospective cohort study with a prediction model.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Pancreatitis in patients with hematologic malignancies, particularly lymphoma, is a challenging complication with heterogeneous etiologies. Large studies with systematic etiological classification and prognostic models are lacking. Methods: This retrospective multicenter study (2020-2025) included patients with hematologic malignancies who developed acute pancreatitis. Etiologies were adjudicated using predefined criteria. A nomogram-based prediction model was developed with internal bootstrap validation. Results: Among 1,705 patients, 31 (1.82%) developed pancreatitis: 19 lymphoma (61.3%), 9 leukemia (29.0%), and 3 plasma cell disorders (9.7%). In the lymphoma cohort (median age 59 years, 57.9% male), diffuse large B-cell lymphoma (47.4%) and peripheral T-cell lymphoma (PTCL) (21.1%) were most common. Etiology distribution: treatment-related (36.8%), direct pancreatic infiltration (31.6%), conventional (15.8%), multifactorial (10.5%), and infection-related (5.3%). Endoscopic ultrasound (EUS)-guided tissue acquisition had 83.3% diagnostic sensitivity for direct infiltration; positron emission tomography/computed tomography (PET-CT) showed a "tetrad sign" in 5/6 cases. Severe pancreatitis occurred in 21.1% of lymphoma-associated pancreatitis. The nomogram (incorporating time to pancreatitis ≤30 days, recent L-asparaginase (LAsp)/immune checkpoint inhibitors (ICIs) exposure, and absence of pancreatic mass) discriminated treatment-related from non-treatment-related etiologies with AUC 0.84 (95% CI 0.71-0.96). PTCL subtype (HR 3.12, 95% CI 1.28-7.61, p=0.012), multifactorial etiology (HR 2.56, 95% CI 1.02-6.42, p=0.045), and age ≥65 years (HR 2.01, 95% CI 0.95-4.25, p=0.07) predicted 1-year mortality (C-index 0.79). Summary: Lymphoma-associated pancreatitis is rare (1.8% of hematologic malignancies). Treatment-related causes slightly outnumber direct infiltration. EUS-guided tissue acquisition and PET-CT are valuable for differential diagnosis. The nomogram may assist etiological classification and risk stratification, but prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.